UK DAILY MAIL: SWISS firm TURING PHARM AB bought Marketing Rights to DARAPRIM (PYRIMETHAMINE)

• Martin Shkreli, 32, founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim in August for $55million
• He raised the price of the drug form $13.50 per tablet to $750 per tablet
• Shkreli has backed the decision, saying that his company 'need to turn a profit on the drug'
• Daraprim treats toxoplasmois, an opportunistic parasitic infection that can cause serious and life-threatening problems

Read more: http://www.dailymail.co.uk/news/article-3243938/Ex-hedge-funder-32-hated-man-internet-defends-jacking-prices-AIDS-medication-5500.html#ixzz3mQEiCDlI
Follow us: @MailOnline on Twitter | DailyMail on Facebook